RA Capital’s TechAtlas team is currently accepting summer internship applications for 2023. Three of last year’s interns - Drew Biedermann, Ross Chikarmane, and Gabe Fox - are now permanent members of the TechAtlas team. Read their perspectives on their internship experience.

At RA Capital, we love our TechAtlas team and the super detailed Landscape Maps they create to help us understand what can otherwise be an overwhelming amount of information. These maps explain the comparative strengths and weaknesses of as many as hundreds of competitive and complementary technologies, drugs, devices, and diagnostics in various stages of development for a particular disease or condition. Think of them like medical treasure maps that lead to the most promising technologies and companies in any given disease area. You can probably understand why we can’t afford to do all that work and just publish the maps freely for the whole world to study.

Then COVID came along.

Members of TechAtlas work closely with the Investment Team and our portfolio companies to put data into context, identify breakthroughs, and develop conviction about how to solve particular problems given what we know of all the different technologies in development.

In this month’s episode, we discuss the latest COVID news. Then Peter Kolchinsky talks with our guest, Dr. Joshua Cohen of Tufts Medical Center, about how they estimate the value of a drug.

In this month’s episode of RA TV, we look back at the past year for biotech, examine today’s headlines, and contemplate the future of this pandemic — and maybe the next one.

Listen in as RA Capital’s TechAtlas Associates convene to discuss recent Covid-19 news. Learn about the emerging Delta variant, new data from Novavax and CureVac, and the potential association between mRNA vaccines and myocarditis.

Given the seemingly endless supply of COVID-19-related content, it has sometimes felt like I was passively binging on round-the-clock coverage that was more distracting than edifying. So what might I have missed while I was absorbed in COVID? As it turns out, quite a lot.

Listen in as RA Capital’s TechAtlas Associates convene to discuss recent Covid-19 news. Learn about the emerging Delta variant, new data from Novavax and CureVac, and the potential association between mRNA vaccines and myocarditis.